Stay updated on Nivolumab and Relatlimab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedA new Revision: v3.6.4 tag has been added. The previous Revision: v3.6.3 tag, along with certain related topics text (Melanoma, MedlinePlus Genetics), was removed.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check28 days agoChange DetectedMetadata and related topics were updated, and the revision tag was changed from v3.6.2 to v3.6.3. These changes adjust navigation and context without altering the study details.SummaryDifference0.2%

- Check36 days agoChange DetectedThe page’s revision label was updated from v3.6.0 to v3.6.2 to reflect a new build. This update records the updated software version without changing the page’s content or functionality.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded related topic tags for Melanoma and MedlinePlus Genetics. These additions connect the study page with broader melanoma-related and genetics resources, providing quick access to contextual materials.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now indicates that the study is no longer recruiting participants and adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention / Treatment label was updated to Intervention/Treatment and the site revision is updated to v3.6.0 from v3.5.5.SummaryDifference0.4%

- Check57 days agoChange DetectedThe page revision was updated to v3.5.5 and certain unrelated topics (e.g., Melanoma and MedlinePlus Genetics) were removed from the related topics, reflecting metadata cleanup rather than a change to study details.SummaryDifference0.2%

Stay in the know with updates to Nivolumab and Relatlimab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in Melanoma Clinical Trial page.